Langbahn Team – Weltmeisterschaft

LG121071

LG121071
Clinical data
Other namesLG-121071; LGD-121071
Identifiers
  • 6-Ethyl-4-(trifluoromethyl)-1H,2H,6H,7H,8H,9H-pyrido[3,2-g]quinolin-2-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H15F3N2O
Molar mass296.293 g·mol−1
3D model (JSmol)
  • CCC1CCNC2=C1C=C3C(=CC(=O)NC3=C2)C(F)(F)F
  • InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21)
  • Key:SZPPQFARTYXRKU-UHFFFAOYSA-N

LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered.[1][2] It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine).[2] The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM),[2] with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT).[3] Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects.[4] In accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids.[5]

The in vitro metabolism of LG121071 has been characterized in anticipation of its possible use as a doping agent.[5][6]

See also

References

  1. ^ Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK (January 1999). "Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)". Journal of Medicinal Chemistry. 42 (2): 210–212. doi:10.1021/jm9806648. PMID 9925725.
  2. ^ a b c Gao W, Kim J, Dalton JT (August 2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–1658. doi:10.1007/s11095-006-9024-3. PMC 2072875. PMID 16841196.
  3. ^ Chengalvala M, Oh T, Roy AK (2005). "Selective androgen receptor modulators". Expert Opinion on Therapeutic Patents. 13 (1): 59–66. doi:10.1517/13543776.13.1.59. ISSN 1354-3776. S2CID 219188263.
  4. ^ Elbers JM, Grootenhuis AJ (April 2003). "New tissue-selective androgens: perspectives in the treatment of androgen deficits". Annales d'Endocrinologie. 64 (2): 183–188. PMID 12773961.
  5. ^ a b Knoop A, Krug O, Vincenti M, Schänzer W, Thevis M (2015). "In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry". European Journal of Mass Spectrometry. 21 (1): 27–36. doi:10.1255/ejms.1328. PMID 25906032. S2CID 29918434.
  6. ^ Gerace E, Salomone A, Fasano F, Costa R, Boschi D, Di Stilo A, Vincenti M (April 2011). "Validation of a GC/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis". Analytical and Bioanalytical Chemistry. 400 (1): 137–144. doi:10.1007/s00216-010-4569-8. hdl:2318/86557. PMID 21165606. S2CID 43268790.
Quelle: http://en.wikipedia.org/wiki/LG121071